



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 19, 2025

Hans van Houte  
Chief Financial Officer  
Nurix Therapeutics, Inc.  
1700 Owens Street, Suite 205  
San Francisco, CA 94158

**Re: Nurix Therapeutics, Inc.**  
**Form 10-K for Fiscal Year Ended November 30, 2024**  
**File No. 001-39398**

Dear Hans van Houte:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences